Of the 76,101 drug samples examined in the country last fiscal, over 2,500 did not meet the prescribed quality standards, while more than 200 were found to be spurious, the government told the Rajya Sabha Tuesday.
Answering a query in the Upper House, Minister of State for Health Ashwini Kumar Choubey said the figures were provided by the drugs controllers of various states and Union Territories.
He said that of the 76,101 medicine samples tested in 2018-19, 2,549 were found to be substandard and 205 were adulterated.
The minister said the government is committed to ensuring that the quality, safety and efficacy of drugs are not compromised.
Asked about the steps being taken in this regard, he said the government has put in place several measures including "strengthening of legal provisions, conducting workshops and training programmes for manufacturers and regulatory officials and measures such as risk based inspections."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
